Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion Dec 20, 2010 12:51pm

195 Views

Post# 17871088

RE: RE: RE: RE: RE: RE: RE: RE: More Manipulator F

Thank you for the correction. I was going by memory and I thought Dinning's appointment would get the investors of Calgary excited. Livonen was CEO of the Canadian branch plant. Hard to believe his appointment could cause a stir. Can you explain why the we are only 20% higher than 2009 high due to the announcement of the head & neck pivotal trial? I credit the limited performance to you and the other members of the investment club.

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi